CHRM1
Muscarinic acetylcholine receptor M1
As of the edition of 20 October 2026, CHRM1 (muscarinic acetylcholine receptor M1, UniProt P11229) has 42 drugs tested at it and 57 companies on the list, 4 on route A and 11 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P11229
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 7
- Disease areas
- Lungs and airways; Eye; Mental health; Nervous system; Skin and connective tissue; Immune system; Cancer; Heart and blood vessels
- Registered trials of its drugs
- 459
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 28 |
| Active | 1 |
| Went quiet | 5 |
| Stopped | 6 |
| Withdrawn from market | 2 |
| Total | 42 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Glycopyrronium | Marketed | Phase 4 | none listed |
| Atropine | Marketed | Phase 4 | none listed |
| Scopolamine | Marketed | Phase 4 | none listed |
| Pilocarpine | Marketed | Phase 4 | none listed |
| Xanomeline | Marketed | Phase 4 | none listed |
| Darotropium | Went quiet | Phase 2 | none listed |
| Benztropine | Marketed | Phase 4 | none listed |
| Sofpironium | Marketed | Phase 3 | Ends 2040 |
| Talsaclidine | Stopped | Phase 3 | none listed |
| Biperiden | Marketed | Phase 4 | none listed |
| AGN-190584 | Stopped | Phase 4 | none listed |
| ASM-024 | Stopped | Phase 2 | none listed |
12 of 42 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 4 |
| Route B | 11 |
| Engaged | 24 |
| Undetermined | 18 |
| Total on the list | 57 |
| Company | Route |
|---|---|
| Novartis | Route B |
| Boehringer Ingelheim | Route A |
| Roche | Route B |
The other 54 companies at CHRM1
In the product57 companies in all; 54 are not named here, and no score is.
See the 57 companies at CHRM1, ranked, with the facts behind eachRequest access. Nothing is shown until you do.